Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of MT-2990 in Healthy Male Subjects
NCT03156738Phase 1Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- May 2017
- Primary completion
- Dec 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MT-2990 in endometriosis (5 arms), sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoints: Incidence, nature and severity of adverse events, Vital signs and 3 more. Started May 2017; status: completed.
02
Drugs
MT-2990
03
Conditions
endometriosis
Beyond the preview
Go deeper on NCT03156738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03156738.